Get the Stockscreener App
5.03
0.00%
0.00
After Hours:
5.00
-0.03
-0.60%
Mannkind Corp stock is traded at $5.03, with a volume of 2.96M.
It is up +0.00% in the last 24 hours and down -5.81% over the past month.
See More
Previous Close:
$5.03
Open:
$4.96
24h Volume:
2.96M
Relative Volume:
1.47
Market Cap:
$1.55B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
100.60
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
-3.82%
1M Performance:
-5.81%
6M Performance:
-20.03%
1Y Performance:
+11.04%
1-Day Range:
$4.89
$5.06
1-Week Range:
$4.89
$5.265
52-Week Range:
$3.97
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.03 | 1.55B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
Cantor maintains Overweight rating on MannKind stock at $9 target - Investing.com
Why It's Worth Keeping An Eye On MannKind - RTTNews
Inhalable Biologics Industry Report 2025: World Market to Nearly Triple in Size by 2030, Reaching $10.06 Billion at a CAGR of 17.6% - Yahoo Finance
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com India
MAC Lung Disease Market Statistics Expected to Experience Major - openPR
MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025 - Nasdaq
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 - Yahoo Finance
AllPennyStocks.com News: Companies Looking Towards Future Revenue with New Diabetes Therapies - ACCESS Newswire
Commit To Purchase MannKind At $3, Earn 13.3% Using Options - Nasdaq
Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart
Non- Tuberculous Mycobacterial Infections Market on Track - openPR
MannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’ - MSN
MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
MannKind Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Decoding MannKind Corp (MNKD): A Strategic SWOT Insight - GuruFocus.com
MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question - Seeking Alpha
MannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call Transcript - Insider Monkey
MannKind: Q4 Earnings Snapshot - mySA
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Re - GuruFocus.com
MannKind Corp Q4 Earnings: EPS Meets Estimates at $0.03, Revenue Surpasses Expectations at $77 Million - GuruFocus.com
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Mannkind stock gains amid Q4 report, business update - MSN
MannKind Corp reports results for the quarter ended December 31Earnings Summary - TradingView
MannKind (MNKD) Q4 Earnings Meet Estimates - Yahoo Finance
Earnings call transcript: MannKind Q4 2024 beats EPS forecast, stock jumps - Investing.com
MannKind earnings beat by $0.05, revenue topped estimates - Investing.com
MannKind shares move 4% higher on strong revenue growth By Investing.com - Investing.com South Africa
MannKind shares move 4% higher on strong revenue growth - Investing.com
MANNKIND CORP SEC 10-K Report - TradingView
MannKind Corp (MNKD) Q4 2024 Earnings Report Preview: What To Expect - Yahoo Finance
Unveiling MannKind (MNKD) Q4 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
MannKind: Q2 Earnings Snapshot -August 07, 2024 at 08:09 am EDT - Marketscreener.com
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025 - Yahoo Finance
MannKind Sets Stage for 2024 Performance Review: CEO and CFO to Unveil Full Year Results - Stock Titan
MannKind (MNKD) Expected to Announce Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage on MannKind (NASDAQ:MNKD) - MarketBeat
MannKind To Present At Oppenheimer Healthcare Life Sciences Conference; Webcast At 11:20 AM ET - Nasdaq
An Analysis of Mannkind Corp (MNKD)’s Potential Price Growth - Knox Daily
MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wedbush - Defense World
Investing in Fortuna Mining Corp (FSM) Is Getting More Attractive - Knox Daily
MannKind Co. (NASDAQ:MNKD) Shares Sold by Calamos Advisors LLC - MarketBeat
There is no doubt that Mannkind Corp (MNKD) ticks all the boxes. - SETE News
MannKind to Present at Upcoming Investor Conferences - Yahoo Finance
MNKD Shares Experience Surge in Value - Knox Daily
MannKind Executives Set for Strategic Presentations at Elite Healthcare Investment Forums - StockTitan
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
(02/03/25) Top Picks 2025: MannKind (MNKD) - Moneyshow.com
MannKind Corporation's (NASDAQ:MNKD) institutional investors lost 4.0% over the past week but have profited from longer-term gains - Yahoo Finance
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):